Publication
Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (15)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 15
- cancerAcral Lentiginous Melanomacivic_curation1.00
- cancerCutaneous Melanomacivic_curation1.00
- cancerMelanomacivic_curation1.00
- cancerMucosal Melanomacivic_curation1.00
- drugBelvarafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneNRAScivic_curation1.00
- geneRAF1civic_curation1.00
- variantBRAF Fusioncivic_curation1.00
- variantNRAS G12Acivic_curation1.00
- variantNRAS G13Rcivic_curation1.00
- variantNRAS Q61Kcivic_curation1.00
- variantNRAS Q61Lcivic_curation1.00
- variantNRAS Q61Rcivic_curation1.00
- variantRAF1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (10)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 38470950
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRAS G13R1 | ||||||||
| Belvarafenib | Acral Lentiginous Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13214A patient with acral melanoma harboring NRAS G13R received belvarafenib monotherapy after four prior lines of systemic therapy and achieved stable disease as the best RECIST response. The patient rece… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| NRAS Q61K2 | ||||||||
| Belvarafenib | Acral Lentiginous Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13218A patient with acral melanoma harboring NRAS Q61K received belvarafenib as first-line therapy for metastatic disease after progression on adjuvant pembrolizumab and achieved stable disease as the best… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| 〃 | Melanoma | Predictive | C | Supports Resistance | 2 | submitted | EID13217Two patients with NRAS Q61K-mutant melanoma treated with belvarafenib had progressive disease as their best RECIST response. One patient progressed after 1.6 months and the other after 1.4 months of t… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| RAF1 Fusion1 | ||||||||
| Belvarafenib | Cutaneous MelanomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13152A patient with recurrent melanoma harboring a MIPOL1-RAF1 fusion with an intact RAF1 kinase domain received belvarafenib after progression following pembrolizumab with radiotherapy. Belvarafenib was i… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| BRAF Fusion1 | ||||||||
| Belvarafenib | Melanoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID13151A patient with metastatic melanoma of unknown primary harboring an AGK-BRAF fusion with an intact BRAF kinase domain received belvarafenib 450 mg twice daily after progression on pembrolizumab, dacarb… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| NRAS G12A1 | ||||||||
| Belvarafenib | Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13153A patient with melanoma harboring NRAS G12A received belvarafenib monotherapy after two prior lines of systemic therapy and achieved a partial response as the best RECIST response. Belvarafenib treatm… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| NRAS Q61H1 | ||||||||
| Belvarafenib | Melanoma | Predictive | C | Supports Resistance | 2 | submitted | EID13216A patient with melanoma harboring NRAS Q61H received belvarafenib monotherapy after two prior lines of systemic therapy and had progressive disease as the best RECIST response. The patient received be… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| NRAS Q61R2 | ||||||||
| Belvarafenib | Melanoma | Predictive | C | Supports Resistance | 2 | submitted | EID13219A patient with cutaneous melanoma harboring NRAS Q61R received belvarafenib monotherapy after two prior lines of systemic therapy and had progressive disease as the best RECIST response. The patient r… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| 〃 | Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13220A patient with melanoma harboring NRAS Q61R received belvarafenib monotherapy after one prior line of systemic therapy and achieved stable disease as the best RECIST response. At the October 2023 data… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |
| NRAS Q61L1 | ||||||||
| Belvarafenib | Mucosal Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13215A patient with mucosal melanoma harboring NRAS Q61L received belvarafenib monotherapy after five prior lines of systemic therapy and achieved a confirmed partial response by RECIST. The patient receiv… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC | civic |